|
Osteosarcoma
|
0.450 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study identifies two susceptibility loci for osteosarcoma.
|
23727862 |
2013 |
|
Osteosarcoma
|
0.450 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies two susceptibility loci for osteosarcoma.
|
23727862 |
2013 |
|
Osteosarcoma
|
0.450 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study identifies two susceptibility loci for osteosarcoma.
|
23727862 |
2013 |
|
Epilepsy, Temporal Lobe
|
0.300 |
Biomarker
|
disease |
CTD_human |
Here, we examine the transcription levels of mGluRs class I (mGluR1 and 5) and III (mGluR4 and 7) in experimental TLE and correlate differential mGluR subunit expression with mouse-strain-dependent susceptibility to TLE induced by pilocarpine.
|
15694259 |
2005 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the effects of mGluR4 on the growth and apoptosis of the LN229 GBM cell line.
|
29867331 |
2018 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
High mGluR4 expression is more frequently noted in the osteosarcoma tissues with higher Enneking stage and metastasis.
|
24399291 |
2014 |
|
CNS disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
However, further elucidation of the biological properties of the mGlu4 receptor, including expression and its signalling profile in distinct tissues and cells are still awaited in order to establish the mGlu4 receptor as a definite drug target in several CNS and non-CNS diseases.
|
29486616 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
In recent years, the survey of metabolic glutamate receptor 4 (GRM4) in tumor biology has been gradually concerned.
|
31581881 |
2020 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
In vivo study showed that mGluR4 activation significantly inhibited tumor growth of bladder cancer via suppressing proliferation and promoting apoptosis.
|
30145816 |
2019 |
|
Epilepsy
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Localization of the human mGluR4 gene within an epilepsy susceptibility locus(1).
|
11223165 |
2001 |
|
Colonic Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
Metabotropic glutamate receptor 4-mediated 5-Fluorouracil resistance in a human colon cancer cell line.
|
15217955 |
2004 |
|
Parkinson Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
Modulation of presynaptic metabotropic glutamate receptor 4 (mGlu<sub>4</sub>) by an allosteric ligand has been proposed as a promising therapeutic target in Parkinson's disease and levodopa-induced dyskinesia.
|
30066121 |
2019 |
|
Dyskinetic syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Modulation of presynaptic metabotropic glutamate receptor 4 (mGlu<sub>4</sub>) by an allosteric ligand has been proposed as a promising therapeutic target in Parkinson's disease and levodopa-induced dyskinesia.
|
30066121 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Nevertheless, the PTEN-specific inhibitor significantly abolished the mGluR4 activation-induced cell apoptosis and proliferative inhibition in bladder cancer cell lines.
|
30145816 |
2019 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Nevertheless, the PTEN-specific inhibitor significantly abolished the mGluR4 activation-induced cell apoptosis and proliferative inhibition in bladder cancer cell lines.
|
30145816 |
2019 |
|
Carcinoma of bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Nevertheless, the PTEN-specific inhibitor significantly abolished the mGluR4 activation-induced cell apoptosis and proliferative inhibition in bladder cancer cell lines.
|
30145816 |
2019 |
|
Mitral Valve Stenosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
No mGluR4 IR was detected in cells of the microglia/macrophage lineage in the MS lesions studied.
|
15589052 |
2005 |
|
Multiple Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
No mGluR4 IR was detected in cells of the microglia/macrophage lineage in the MS lesions studied.
|
15589052 |
2005 |
|
Juvenile Myoclonic Epilepsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
Nominally significant associations were detected between IGE and seven GRM4 SNPs (with P-values ranging from 0.037 to 0.0036), between JME and five SNPs (P=0.042-0.0106), and between CAE and two SNPs (P=0.0466-0.0021).
|
20338729 |
2010 |
|
Juvenile Myoclonic Epilepsy
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Of variants investigating in independent data sets, only rs2029461 SNP in GRM4, rs3743123 in CX36 and rs3918149 in BRD2 showed a significant association with JME in at least two different background populations.
|
28636645 |
2017 |
|
Neoplasm Metastasis
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
Our data suggest that GRM4 gene polymorphism is closely related to the morbidity and metastasis of osteosarcoma in a Chinese population.
|
26276359 |
2016 |
|
Juvenile Myoclonic Epilepsy
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Our results provide no evidence that genetic variation of the GRM4 gene confers susceptibility to JME-related IGE syndromes.
|
14582146 |
2003 |
|
Idiopathic generalized epilepsy
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Our results provide no evidence that genetic variation of the GRM4 gene confers susceptibility to JME-related IGE syndromes.
|
14582146 |
2003 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Our results suggest that GRM4 might be a tumor suppressor gene in breast cancer under the direct regulation of miR-328-3p and miR-370-3p.
|
31492116 |
2019 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Overexpression of GRM4 could significantly inhibit cell proliferation, migration and invasion capacity in MDA-MB-231, while knockdown of GRM4 could promote these processes. miR-328-3p and miR-370-3p were predicted to regulate the expression of GRM4 and dual luciferase reporter assay demonstrated that miR-328-3p and miR-370-3p directly bound to the 3' UTR of GRM4 and mutations on the binding regions on GRM4 significantly decreased the luciferase activity. qPCR demonstrated that expression of miR-328-3p and miR-370-3p was significantly decreased in breast cancer tissues and cells compared with that in control samples.
|
31492116 |
2019 |